LifeStance Health Group (NASDAQ:LFST) Given New $12.00 Price Target at BTIG Research

LifeStance Health Group (NASDAQ:LFST) had its price objective raised by investment analysts at BTIG Research from $11.00 to $12.00 in a research note issued to investors on Friday,Benzinga reports. The firm presently has a “buy” rating on the stock. BTIG Research’s price target indicates a potential upside of 35.59% from the company’s current price.

LFST has been the subject of a number of other research reports. Jefferies Financial Group upgraded LifeStance Health Group to a “strong-buy” rating in a research report on Thursday, March 12th. UBS Group raised their price objective on LifeStance Health Group from $10.00 to $12.00 and gave the company a “buy” rating in a research report on Thursday, February 26th. Weiss Ratings upgraded LifeStance Health Group from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Friday, February 27th. Canaccord Genuity Group raised their price objective on LifeStance Health Group from $9.00 to $10.00 and gave the company a “buy” rating in a research report on Thursday, February 26th. Finally, KeyCorp raised their price objective on LifeStance Health Group from $8.00 to $9.00 and gave the company an “overweight” rating in a research report on Thursday, February 26th. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Buy” and an average price target of $10.00.

LifeStance Health Group Price Performance

NASDAQ:LFST opened at $8.85 on Friday. The company has a quick ratio of 1.65, a current ratio of 1.65 and a debt-to-equity ratio of 0.17. The business’s 50-day simple moving average is $6.80 and its two-hundred day simple moving average is $6.68. The stock has a market cap of $3.43 billion, a PE ratio of 442.72 and a beta of 1.20. LifeStance Health Group has a 52 week low of $3.74 and a 52 week high of $8.89.

LifeStance Health Group (NASDAQ:LFST) last posted its quarterly earnings results on Thursday, May 7th. The company reported $0.04 EPS for the quarter, beating analysts’ consensus estimates of $0.01 by $0.03. The business had revenue of $403.48 million for the quarter, compared to analysts’ expectations of $387.46 million. LifeStance Health Group had a return on equity of 0.65% and a net margin of 0.68%.The firm’s quarterly revenue was up 21.2% on a year-over-year basis. As a group, analysts forecast that LifeStance Health Group will post 0.09 EPS for the current fiscal year.

LifeStance Health Group declared that its board has approved a stock buyback program on Wednesday, February 25th that authorizes the company to repurchase $100.00 million in shares. This repurchase authorization authorizes the company to buy up to 3.6% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company’s management believes its stock is undervalued.

Insider Activity

In related news, Director Darren M. Black sold 4,314,939 shares of LifeStance Health Group stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $7.01, for a total value of $30,247,722.39. Following the completion of the transaction, the director owned 29,209,776 shares in the company, valued at approximately $204,760,529.76. This trade represents a 12.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Robert Bessler sold 62,147 shares of LifeStance Health Group stock in a transaction dated Friday, April 24th. The stock was sold at an average price of $7.05, for a total value of $438,136.35. Following the completion of the transaction, the director owned 1,274,448 shares of the company’s stock, valued at approximately $8,984,858.40. This represents a 4.65% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 4,389,939 shares of company stock valued at $30,775,881. 3.20% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Assetmark Inc. boosted its position in shares of LifeStance Health Group by 17.0% during the first quarter. Assetmark Inc. now owns 9,419 shares of the company’s stock valued at $60,000 after buying an additional 1,367 shares during the period. Park Edge Advisors LLC boosted its position in shares of LifeStance Health Group by 14.4% during the fourth quarter. Park Edge Advisors LLC now owns 11,863 shares of the company’s stock valued at $84,000 after buying an additional 1,495 shares during the period. California State Teachers Retirement System boosted its position in shares of LifeStance Health Group by 1.6% during the fourth quarter. California State Teachers Retirement System now owns 125,682 shares of the company’s stock valued at $885,000 after buying an additional 1,966 shares during the period. Vident Advisory LLC boosted its position in shares of LifeStance Health Group by 12.7% during the second quarter. Vident Advisory LLC now owns 21,732 shares of the company’s stock valued at $112,000 after buying an additional 2,447 shares during the period. Finally, Xponance LLC boosted its position in shares of LifeStance Health Group by 26.4% during the fourth quarter. Xponance LLC now owns 13,144 shares of the company’s stock valued at $93,000 after buying an additional 2,745 shares during the period. Hedge funds and other institutional investors own 85.50% of the company’s stock.

Key LifeStance Health Group News

Here are the key news stories impacting LifeStance Health Group this week:

• Positive Sentiment: Q1 beat — LifeStance reported $0.04 EPS (vs. $0.01 consensus) and revenue of $403.5M, +21% year-over-year, signaling accelerating top-line growth. LifeStance Q1 results (MarketBeat)
• Positive Sentiment: Revenue guidance lifted/confirmed — Management updated Q2 and FY revenue ranges (~$405M–$425M for Q2; ~$1.6B–$1.7B for FY), supporting the beat and giving a clearer growth outlook. LifeStance Q1 press release (GlobeNewswire)
• Positive Sentiment: Analyst sentiment supportive — Brokerages have a consensus Buy on LFST, reinforcing investor confidence after the quarter. Consensus Buy (American Banking News)
• Positive Sentiment: Capital return move — Company authorized a concurrent repurchase of up to 6M shares from the underwriter tied to the offering, which can help offset some selling pressure. Offering + repurchase (QuiverQuant)
• Positive Sentiment: Market reaction — Shares hit a two‑year high as investors priced in the earnings beat and momentum. LFST hits 2-year high (Yahoo)
• Negative Sentiment: Large secondary offering — Selling stockholders priced a 35,000,000‑share secondary at $8.15 per share; LifeStance receives no proceeds. That sizable supply increase can create downward pressure despite the repurchase program. Secondary offering priced (GlobeNewswire)
• Negative Sentiment: Insider & shareholder sales — Recent disclosures and reporting highlight sizable insider/stockholder sales (historical large stakes sold by major holders), which may signal lock-up/liquidity-driven selling pressure. Insider selling & offering context (QuiverQuant)

About LifeStance Health Group

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.